The data showed that prostate adenocarcinoma (PRAD) and diffuse large B-cell lymphoma had a high mutation level with CD68 deep deletion of more than 4% (Fig. 2A,B). This evidence concerns the gene CD68 and diffuse large B-cell lymphoma.